Skip to content
DataLookout
Menu

NCT04002947

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 218 versions: 5 with changes below, 45 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Primary completion pushed from May 31, 2027 to Oct 12, 2027
  2. Notable Eligibility criteria expanded, about 32 words
  3. Notable Primary completion pushed from May 31, 2026 to May 31, 2027
    • Study completion pushed from Mar 31, 2030 to Mar 31, 2031
    v206
  4. Notable Primary completion date: May 31, 2025 to May 31, 2026
    • Study completion date: Mar 31, 2029 to Mar 31, 2030
    v173
  5. Study Status, Eligibilityv169
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Response rate
Timeframe: every 2 cycles

Secondary (5)

Safety and tolerability
Progression-free survival
Overall survival
Event-free survival
Complete response rate

Arms and interventions

1Experimental

Acalabrutinib 100 mg orally twice a day for 14 days; Following window: patients with \> or = to 25% tumor reduction, treat with DA-EPOCH-R or R-CHOP + acalabrutinib 100mg orally twice a day for the first 10 days, for 6 cycles; whereas, patients with \<25% tumor reduction, treat with DA-EPOCH-R or R-CHOP alone for 6 cycles

Drugs: DA-EPOCH, CHOP, Acalabrutinib

Biologicals: Rituximab

Sites

1 site in 1 country

  • National Institutes of Health Clinical CenterBethesda, Maryland, United States